Accelerated memory decline in Alzheimer's disease with apolipoprotein ε4 allele

Journal of Neuropsychiatry and Clinical Neurosciences

Volumn 15, Issue 3, 2003, Pages 354-358

  Hirono, Nobutsugu ^a   Hashimoto, Mamoru ^b   Yasuda, Minoru ^b   Kazui, Hirokazu ^b   Mori, Etsuro ^b  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

AGED; AGING; ALLELE; ALZHEIMER DISEASE; ARTICLE; COGNITION; DEGENERATIVE DISEASE; DEMENTIA; FEMALE; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEMORY; MEMORY DISORDER; NEUROLOGIC DISEASE; PRIORITY JOURNAL; PSYCHOMETRY; RECALL; SCORING SYSTEM;

EID: 0041660781     PISSN: 08950172     EISSN: None     Source Type: Journal    
DOI: 10.1176/jnp.15.3.354     Document Type: Article

References (39)

1. Corder EH, Saunders AM, Strittmatter WJ, et al: Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993; 261:921-923
2. Poirier J, Davignon J, Bouthillier D, et al: Apolipoprotein E polymorphism and Alzheimer's disease. Lancet 1993; 342:697-699
3. Lucotte G, Turpin JC, Landais P: Apolipoprotein E-ε4 allele doses in late-onset Alzheimer's disease. Ann Neurol 1994; 36:681-682
4. Blacker D, Haines JL, Rodes L, et al: ApoE-4 and age at onset of Alzheimer's disease: The NIMH Genetics Initiative. Neurology 1997; 48:139-147
5. Craft S, Teri L, Edland SD, et al: Accelerated decline in apolipoprotein E-epsilon4 homozygotes with Alzheimer's disease. Neurology 1998; 51:149-153
6. Kanai M, Shizuka M, Urakami K, et al: Apolipoprotein E4 accelerates dementia and increases cerebrospinal fluid tau levels in Alzheimer's disease. Neurosci Lett 1999; 267:65-68
7. Basun H, Grut M, Winblad B, et al: Apolipoprotein epsilon 4 allele and disease progression in patients with late-onset Alzheimer's disease. Neurosci Lett 1995; 183:32-34
8. Dal Forno G, Rasmusson DX, Brandt J, et al: Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease. Arch Neurol 1996; 53:345-350
9. Kurz A, Egensperger R, Haupt M, et al: Apolipoprotein E epsilon 4 allele, cognitive decline, and deterioration of everyday performance in Alzheimer's disease. Neurology 1996; 47:440-443
10. Growdon JH, Locascio JJ, Corkin S, et al: Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology 1996; 47:444-448
11. Holmes C, Levy R, McLoughlin DM, et al: Apolipoprotein E: non-cognitive symptoms and cognitive decline in late onset Alzheimer's disease. J Neurol Neurosurg Psychiatry 1996; 61:580-583
12. Murphy GM Jr, Taylor J, Kraemer HC, et al: No association between apolipoprotein E epsilon 4 allele and rate of decline in Alzheimer's disease. Am J Psychiatry 1997; 154:603-608
13. Lehtovirta M, Kuikka J, Helisalmi S, et al: Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatry 1998; 64:742-746
14. Slooter AJ, Houwing-Duistermaat JJ, van Harskamp F, et al: Apolipoprotein E genotype and progression of Alzheimer's disease: the Rotterdam Study. J Neurol 1999; 246:304-308
15. Farlow MR, Cyrus PA, Nadel A, et al: Metrifonate treatment of AD: influence of APOE genotype. Neurology 1999; 53:2010-2016
16. Raskind MA, Peskind ER, Wessel T, et al: Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 2000; 54:2261-2268
17. Aerssens J, Raeymaekers P, Lilienfeld S, et al: APOE genotype: no influence on galantamine treatment efficacy nor on rate of decline in Alzheimer's disease. Dement Geriatr Cogn Disord 2001; 12:69-77
18. Mori E, Lee K, Yasuda M, et al: Accelerated hippocampal atrophy in Alzheimer's disease with Apolipoprotein E ε4 allele. Ann Neurol 2002; 51:209-214
19. Frisoni GB, Govoni S, Geroldi C, et al: Gene dose of the epsilon 4 allele of apolipoprotein E and disease progression in sporadic late-onset Alzheimer's disease. Ann Neurol 1995; 37:596-604
20. Stern Y, Brandt J, Albert M, et al: The absence of an apolipoprotein epsilon4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 1997; 41:615-620
21. Mayeux R, Small SA, Tang M, et al: Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol Aging 2001; 22:683-689
22. Dik MG, Jonker C, Bouter LM, et al: APOE-epsilon4 is associated with memory decline in cognitively impaired elderly. Neurology 2000; 54:1492-1497
23. Moffat SD, Szekely CA, Zonderman AB, et al: Longitudinal change in hippocampal volume as a function of apolipoprotein E genotype. Neurology 2000; 55:134-136
24. Lehtovirta M, Laakso MP, Soininen H, et al: Volumes of hippocampus, amygdala and frontal lobe in Alzheimer's patients with different apolipoprotein E genotypes. Neuroscience 1995; 67:65-72
25. Lehtovirta M, Soininen H, Helisalmi S, et al: Clinical and neuropsychological characteristics in familial and sporadic Alzheimer's disease: relation to apolipoprotein E polymorphism. Neurology 1996; 46:413-419
26. Lehtovirta M, Soininen H, Laakso MP, et al: SPECT and MRI analysis in Alzheimer's disease: relation to apolipoprotein E ε4 allele. J Neurol Neurosurg Psychiatry 1996; 60:644-649
27. Geroldi C, Pihlajamaki M, Laakso MP, et al: APOE-epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology 1999; 53:1825-1832
28. Bigler ED, Lowry CM, Anderson CV, et al: Dementia, quantitative neuroimaging, and apolipoprotein E genotype. AJNR Am J Neuroradiol 2000; 21:1857-1868
29. Hashimoto M, Yasuda M, Tanimukai S, et al: Apolipoprotein E ε4 and the pattern of regional brain atrophy in Alzheimer's disease. Neurology 2001; 57:1461-1466
30. Hirono N, Hashimoto M, Yasuda M, et al: The effect of APOE e4 allele on cerebral glucose metabolism in AD is a function of age at onset. Neurology 2002; 58:743-750
31. Schmechel DE, Saunders AM, Strittmatter WJ, et al: Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci U S A 1993; 90:9649-9653
32. Berg L, McKeel DW Jr, Miller JP, et al: Clinicopathologic studies in cognitively healthy aging and Alzheimer's disease: relation of histologic markers to dementia severity, age, sex, and apolipoprotein E genotype. Arch Neurol 1998; 55:326-335
33. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state for the clinician. J Pschiatr Res 1975; 12:189-198
34. Mohs RC, Rosen WG, Davis KL: The Alzheimer's Disease Assessment Scale; An instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19:448-450
35. McKhann G, Drachman D, Folstein M, et al: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology 1984; 34:939-944
36. Yasuda M, Maeda K, Shimada K, et al: Apolipoprotein E ε4 allele and gender difference in risk of Alzheimer's disease. Alzheimer Res 1995; 1:77-81
37. Wenham PR, Price WH, Blandell G: Apolipoprotein E genotyping by one-stage PCR. Lancet 1991; 337:1158-1159
38. Stern RG, Mohs RC, Davidson M, et al: A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry 1994; 151:390-396
39. Mayeux R, Sano M: Treatment of Alzheimer's disease. N Engl J Med 1999; 341:1670-1679